Skip to main content
Industry News
Poor-risk AML patients may benefit from novel induction cycle

Data from an early-stage trial assessing an induction cycle consisting of Janssen Cilag's Dacogen, or decitabine, succeeded twice a week by Karyopharm Therapeutics' Xpovio, or selinexor, resulted in significant clinical activity in 25 poor-risk patients with relapsed or refractory acute myeloid leukemia, five of whom were older patients newly diagnosed with AML. Details of the trial were reported in online in the journal Leukemia & Lymphoma.

Full Story: